# Sight Sciences, Inc.: overview SGHT · Nasdaq · CIK 1531177 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/sght.md) · [Financials](/companies/sght/financials.md) · [Filings](/companies/sght/filings.md) · [Insiders](/companies/sght/insiders.md) Latest reported revenue: [$23.4m](/filings/0001193125-26-335204.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-335204). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [20.2](/filings/0001193125-25-269613.md) | [19.1 d](/filings/0001193125-26-091558.md) | [17.5](/filings/0001193125-26-209116.md) | [19.6](/filings/0001193125-26-335204.md) | [19.9](/filings/0001193125-25-269613.md) | [20.4 d](/filings/0001193125-26-091558.md) | [19.7](/filings/0001193125-26-209116.md) | [23.4](/filings/0001193125-26-335204.md) | | Gross margin | % | [83.9%](/filings/0001193125-25-269613.md) | [86.8% d](/filings/0001193125-26-091558.md) | [86.2%](/filings/0001193125-26-209116.md) | [84.8%](/filings/0001193125-26-335204.md) | [86.4%](/filings/0001193125-25-269613.md) | [87.3% d](/filings/0001193125-26-091558.md) | [86.2%](/filings/0001193125-26-209116.md) | [91.4%](/filings/0001193125-26-335204.md) | | Operating margin | % | [(55.7%)](/filings/0001193125-25-269613.md) | [(62.5%) d](/filings/0001193125-26-091558.md) | [(79.2%)](/filings/0001193125-26-209116.md) | [(59.6%)](/filings/0001193125-26-335204.md) | [(39.7%)](/filings/0001193125-25-269613.md) | [(18.0%) d](/filings/0001193125-26-091558.md) | [(63.0%)](/filings/0001193125-26-209116.md) | [(16.6%)](/filings/0001193125-26-335204.md) | | Net margin | % | [(54.9%)](/filings/0001193125-25-269613.md) | [(62.1%) d](/filings/0001193125-26-091558.md) | [(80.8%)](/filings/0001193125-26-209116.md) | [(61.0%)](/filings/0001193125-26-335204.md) | [(41.0%)](/filings/0001193125-25-269613.md) | [(20.4%) d](/filings/0001193125-26-091558.md) | [(65.9%)](/filings/0001193125-26-209116.md) | [(19.0%)](/filings/0001193125-26-335204.md) | | Diluted EPS | $ per share | [(0.22)](/filings/0001193125-25-269613.md) | not reported | [(0.28)](/filings/0001193125-26-209116.md) | [(0.23)](/filings/0001193125-26-335204.md) | [(0.16)](/filings/0001193125-25-269613.md) | not reported | [(0.24)](/filings/0001193125-26-209116.md) | [(0.08)](/filings/0001193125-26-335204.md) | | Free cash flow | $m | [0.3 d](/filings/0001193125-25-269613.md) | [(3.6) d](/filings/0001193125-26-091558.md) | [(11.6)](/filings/0001193125-26-209116.md) | [(7.8) d](/filings/0001193125-26-335204.md) | [(8.9) d](/filings/0001193125-25-269613.md) | [(2.0) d](/filings/0001193125-26-091558.md) | [(7.1)](/filings/0001193125-26-209116.md) | [(5.7) d](/filings/0001193125-26-335204.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [49.0](/filings/0000950170-23-008526.md) | [71.3](/filings/0000950170-24-030278.md) | [81.1](/filings/0000950170-25-035500.md) | [79.9](/filings/0001193125-26-091558.md) | [77.4](/filings/0001193125-26-091558.md) | | Gross margin | % | [82.4%](/filings/0000950170-23-008526.md) | [82.7%](/filings/0000950170-24-030278.md) | [85.3%](/filings/0000950170-25-035500.md) | [85.5%](/filings/0001193125-26-091558.md) | [86.2%](/filings/0001193125-26-091558.md) | | Operating margin | % | [(105.2%)](/filings/0000950170-23-008526.md) | [(117.7%)](/filings/0000950170-24-030278.md) | [(70.7%)](/filings/0000950170-25-035500.md) | [(63.3%)](/filings/0001193125-26-091558.md) | [(48.0%)](/filings/0001193125-26-091558.md) | | Net margin | % | [(128.6%)](/filings/0000950170-23-008526.md) | [(120.9%)](/filings/0000950170-24-030278.md) | [(68.5%)](/filings/0000950170-25-035500.md) | [(64.5%)](/filings/0001193125-26-091558.md) | [(49.7%)](/filings/0001193125-26-091558.md) | | Diluted EPS | $ per share | [(2.36)](/filings/0000950170-23-008526.md) | [(1.80)](/filings/0000950170-24-030278.md) | [(1.14)](/filings/0000950170-25-035500.md) | [(1.03)](/filings/0001193125-26-091558.md) | [(0.74)](/filings/0001193125-26-091558.md) | | Free cash flow | $m | [(53.4)](/filings/0000950170-23-008526.md) | [(76.9)](/filings/0000950170-24-030278.md) | [(48.0)](/filings/0000950170-25-035500.md) | [(22.7)](/filings/0001193125-26-091558.md) | [(29.9)](/filings/0001193125-26-091558.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/sght/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Long Focus Capital Management, LLC](/funds/1602716.md) | 2026-06-30 | $20.8m | 3,844,100 | | Added +250,000 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $16.7m | 3,083,108 | | Added +251,176 | | [Americana Partners, LLC](/funds/1797678.md) | 2026-06-30 | $9.1m | 1,679,069 | | Added +52 | | [Pathstone Holdings, LLC](/funds/2011612.md) | 2026-06-30 | $9.1m | 1,678,980 | | Reduced −718,352 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $8.5m | 1,573,815 | | Added +121,125 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $5.2m | 958,565 | | Added +43,121 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $4.5m | 835,452 | | Added +424 | | [B Group, Inc.](/funds/2043476.md) | 2026-06-30 | $3.7m | 970,000 | | Unchanged | | [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $2.2m | 397,558 | | Added +259,041 | | [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $2.1m | 383,512 | | Added +41,831 | ## Recent filings [All 502 filings](/companies/sght/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-10 | 12:21 ET | [8-K](/filings/0001193125-26-341346.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-341346 | | 2026-08-05 | 20:21 ET | [10-Q](/filings/0001193125-26-335204.md) | Quarterly report, period 2026-06-30 | 0001193125-26-335204 | | 2026-08-05 | 20:09 ET | [8-K](/filings/0001193125-26-335092.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-335092 | | 2026-06-05 | 20:06 ET | [8-K](/filings/0001193125-26-259546.md) | 5.07 Shareholder vote results | 0001193125-26-259546 | | 2026-05-06 | 20:30 ET | [10-Q](/filings/0001193125-26-209116.md) | Quarterly report, period 2026-03-31 | 0001193125-26-209116 | | 2026-05-06 | 20:08 ET | [8-K](/filings/0001193125-26-208959.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-208959 | | 2026-04-23 | 12:01 ET | [8-K](/filings/0001193125-26-171887.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-171887 | | 2026-04-22 | 20:36 ET | [DEF 14A](/filings/0001140361-26-016138.md) | Proxy statement, period 2026-06-04 | 0001140361-26-016138 | | 2026-03-30 | 11:07 ET | [8-K](/filings/0001193125-26-130386.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-130386 | | 2026-03-04 | 21:19 ET | [10-K](/filings/0001193125-26-091558.md) | Annual report, period 2025-12-31 | 0001193125-26-091558 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-091558.md), filed Mar 4, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/267cd1e6-3dd9-4e27-a68e-f3b7ea4e546b) ## About the filer - CIK: 1531177 - Tickers: SGHT - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.